Equities analysts expect Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) to announce earnings of ($0.50) per share for the current quarter, Zacks reports. Zero analysts have provided estimates for Aeglea Bio Therapeutics’ earnings. The highest EPS estimate is ($0.41) and the lowest is ($0.58). Aeglea Bio Therapeutics posted earnings per share of ($0.49) during the same quarter last year, which suggests a negative year over year growth rate of 2%. The company is expected to issue its next quarterly earnings report on Tuesday, May 14th.

On average, analysts expect that Aeglea Bio Therapeutics will report full-year earnings of ($2.12) per share for the current financial year, with EPS estimates ranging from ($2.53) to ($1.70). For the next year, analysts forecast that the business will report earnings of ($1.77) per share, with EPS estimates ranging from ($2.21) to ($1.33). Zacks’ earnings per share averages are a mean average based on a survey of analysts that that provide coverage for Aeglea Bio Therapeutics.

Aeglea Bio Therapeutics (NASDAQ:AGLE) last announced its earnings results on Thursday, March 7th. The biotechnology company reported ($0.64) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.37) by ($0.27).

A number of equities analysts have weighed in on the stock. Zacks Investment Research lowered shares of Aeglea Bio Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, January 8th. ValuEngine upgraded shares of Aeglea Bio Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, January 5th. Finally, JPMorgan Chase & Co. assumed coverage on shares of Aeglea Bio Therapeutics in a report on Thursday, March 21st. They set an “overweight” rating and a $14.00 target price on the stock. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $20.25.

Shares of AGLE traded down $0.04 during mid-day trading on Monday, reaching $7.21. The company had a trading volume of 43,048 shares, compared to its average volume of 316,808. The firm has a market cap of $207.79 million, a PE ratio of -3.38 and a beta of 1.06. Aeglea Bio Therapeutics has a fifty-two week low of $6.31 and a fifty-two week high of $12.00.

Institutional investors have recently added to or reduced their stakes in the stock. Canada Pension Plan Investment Board purchased a new stake in Aeglea Bio Therapeutics during the fourth quarter valued at $37,000. Meeder Asset Management Inc. increased its stake in Aeglea Bio Therapeutics by 44.9% in the 4th quarter. Meeder Asset Management Inc. now owns 5,116 shares of the biotechnology company’s stock valued at $38,000 after buying an additional 1,585 shares during the period. Bank of America Corp DE increased its stake in Aeglea Bio Therapeutics by 299.9% in the 4th quarter. Bank of America Corp DE now owns 17,145 shares of the biotechnology company’s stock valued at $128,000 after buying an additional 12,858 shares during the period. Millennium Management LLC acquired a new position in Aeglea Bio Therapeutics in the 4th quarter valued at approximately $156,000. Finally, Rhumbline Advisers increased its stake in Aeglea Bio Therapeutics by 48.7% in the 4th quarter. Rhumbline Advisers now owns 21,571 shares of the biotechnology company’s stock valued at $162,000 after buying an additional 7,069 shares during the period. 56.89% of the stock is currently owned by hedge funds and other institutional investors.

About Aeglea Bio Therapeutics

Aeglea BioTherapeutics, Inc, a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in early clinical development stage for the treatment of Arginase 1 deficiency, an autosomal recessive metabolic disease caused by a marked decrease in the activity of the native arginase 1 enzyme; and for treating Arginine dependent cancers.

Recommended Story: Find a Trading Strategy That Works

Get a free copy of the Zacks research report on Aeglea Bio Therapeutics (AGLE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aeglea Bio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.